Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)

The B-cell receptor signaling pathway as a therapeutic target in CLL

(2012) J. A. Woyach et al.   BLOOD

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer

(2012) A. G. Ramsay et al.   BLOOD

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

(2010) Christine I. Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

(2009) A. G. Ramsay et al.   BLOOD

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD